Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Return on Capital Employed: 2020-2025

Historic Return on Capital Employed for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to -0.66%.

  • Foghorn Therapeutics' Return on Capital Employed fell 26.00% to -0.66% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.66%, marking a year-over-year decrease of 26.00%. This contributed to the annual value of -0.47% for FY2024, which is 10.00% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Return on Capital Employed of -0.66% as of Q3 2025, which was down 18.83% from -0.56% recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Return on Capital Employed ranged from a high of -0.23% in Q1 2022 and a low of -0.66% during Q3 2025.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.45% (2023), whereas its average is -0.46%.
  • In the last 5 years, Foghorn Therapeutics' Return on Capital Employed grew by 23bps in 2022 and then declined by 26bps in 2025.
  • Over the past 5 years, Foghorn Therapeutics' Return on Capital Employed (Quarterly) stood at -0.33% in 2021, then grew by 1bps to -0.32% in 2022, then fell by 13bps to -0.45% in 2023, then remained steady at -0.45% in 2024, then dropped by 26bps to -0.66% in 2025.
  • Its Return on Capital Employed was -0.66% in Q3 2025, compared to -0.56% in Q2 2025 and -0.49% in Q1 2025.